Brief: Biomea Announces Positive 52-Week Results From Phase II COVALENT-111 Study In Type 2 Diabetes
06/10/2025 22:43
Oct 6 (Reuters) - Biomea Fusion Inc BMEA.O: BIOMEA FUSION ANNOUNCES POSITIVE 52-WEEK RESULTS FROM PHASE II COVALENT-111 STUDY IN TYPE 2 DIABETES DEMONSTRATING NON-CHRONIC TREATMENT WITH ICOVAMENIB BENEFITS TWO DISTINCT PATIENT POPULATIONS BIOMEA FUSION INC - ICOVAMENIB WELL TOLERATED WITH FAVORABLE SAFETY PROFILE BIOMEA FUSION INC - PHASE II TRIALS EXPECTED TO BEGIN IN Q4 2025 BIOMEA FUSION INC - ICOVAMENIB SHOWS 1.8% PLACEBO ADJUSTED MEAN REDUCTION IN HBA1C (ARM B) AT WEEK 52 BIOMEA FUSION INC - GLP-1 THERAPY NON-RESPONDERS SAW 1.8% HBA1C DROP AT WEEK 52 AFTER 12 WEEKS OF ICOVAMENIB Source text: ID:nGNX9lXtVN Further company coverage: BMEA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biomea Fusion
See all newsUS RESEARCH ROUNDUP-BlackRock, Microsoft, TransDigm Group
Brief: Biomea Fusion Announces Phase 1 Results For Bmf-650, Its Investigational Next-Generation Oral Small Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion To Announce Phase I Results For Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities
Brief: Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes